PE20051049A1 - Composiciones farmaceuticas que comprenden un antagonista de neuroquinina nk1 - Google Patents
Composiciones farmaceuticas que comprenden un antagonista de neuroquinina nk1Info
- Publication number
- PE20051049A1 PE20051049A1 PE2005000022A PE2005000022A PE20051049A1 PE 20051049 A1 PE20051049 A1 PE 20051049A1 PE 2005000022 A PE2005000022 A PE 2005000022A PE 2005000022 A PE2005000022 A PE 2005000022A PE 20051049 A1 PE20051049 A1 PE 20051049A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- antagonist
- sodium
- neuroquinin
- sulfobutilic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO ANTAGONISTA DEL RECEPTOR DE NEUROPEPTIDO NEUROQUININA NK 1, TALES COMO LOS COMPUESTOS DESCRITOS EN LA SOLICITUD DE PATENTE US 20030158173 A1, SIENDO PREFERIDO EL COMPUESTO DE FORMULA (I), ESTOS COMPUESTOS SE ENCUENTRAN MEZCLADOS CON UN DERIVADO POLIANIONICO DE ß-CICLODEXTRINA CON APROXIMADAMENTE 1 O 7 GRUPOS SULFONATO DE SODIO SEPARADOS DE LA CAVIDAD LIPOFILICA POR AL MENOS UN GRUPO ESPACIADOR DE ETER BUTILICO, ESPECIFICAMENTE LA SAL SODICA DE ESTERES SULFOBUTILICOS DE ß-CICLODEXTRINA (CAPTISOL), EL CUAL MEJORA LA SOLUBILIDAD DEL COMPUESTO QUE SE ENCUENTRA EN FORMA DE SAL CLORHIDRICA O DE UNA BASE LIBRE BUFFERIZADA CON ACIDO CITRICO O ACIDO FOSFORICO. ESTA FORMULACION PRESENTA UN Ph DE 4 A 8 Y ADEMAS PUEDEN ESTAR COMPRENDIDA POR: a) UN INHIBIDOR SELECTIVO DE LA RECAPTACION DE SEROTONINA TALES COMO FLUOXETINA, FLUVOXAMINA, PAROXETINA, ENTRE OTROS; b) UN ANTAGONISTA DEL RECEPTOR DE SEROTONINA 5-HT3 TALES COMO ONDANSETRONA, DOLASETRONA, ENTRE OTROS; O c) UNA BENZAMIDA SUSTITUIDA O UN CORTICOSTEROIDE. SON PREFERIDAS LAS FORMULACIONES DE ADMINISTRACION PARENTERAL, SIENDO MAS ESTABLE LA SOLUCION OBTENIDA A PARTIR DE UNA FORMULACION LIOFILIZADA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53173503P | 2003-12-22 | 2003-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051049A1 true PE20051049A1 (es) | 2006-01-03 |
Family
ID=34738689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000022A PE20051049A1 (es) | 2003-12-22 | 2005-01-03 | Composiciones farmaceuticas que comprenden un antagonista de neuroquinina nk1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050153999A1 (es) |
| EP (1) | EP1706116A1 (es) |
| JP (1) | JP2007515425A (es) |
| KR (1) | KR20060113737A (es) |
| CN (1) | CN1897942A (es) |
| AR (1) | AR046769A1 (es) |
| AU (1) | AU2004308935A1 (es) |
| BR (1) | BRPI0417950A (es) |
| CA (1) | CA2550432A1 (es) |
| MX (1) | MXPA06007210A (es) |
| NO (1) | NO20063393L (es) |
| PE (1) | PE20051049A1 (es) |
| PL (1) | PL380482A1 (es) |
| TW (1) | TW200531686A (es) |
| WO (1) | WO2005063243A1 (es) |
| ZA (1) | ZA200605080B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5155998B2 (ja) * | 2006-04-05 | 2013-03-06 | オプコ ヘルス， インコーポレイテッド | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
| PE20080353A1 (es) * | 2006-04-05 | 2008-04-25 | Schering Corp | Sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona y proceso de preparacion de las mismas |
| CA2648604C (en) * | 2006-04-05 | 2016-05-24 | Schering Corporation | Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
| AR066191A1 (es) * | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
| AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| GEP20135806B (en) * | 2008-11-23 | 2013-04-10 | Pfizer | Lactams as beta secretase inhibitors |
| AU2014271269B2 (en) * | 2009-08-14 | 2016-11-03 | Opko Health, Inc. | Intravenous formulations of neurokinin-1 antagonists |
| WO2011019911A1 (en) * | 2009-08-14 | 2011-02-17 | Opko Health, Inc. | Intravenous formulations of neurokinin-1 antagonists |
| BR112014018110B1 (pt) * | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
| NL2018041B1 (en) * | 2016-12-22 | 2018-06-28 | Land Life Company B V | Process to prepare a biodegradable pulp product |
| US10973780B2 (en) * | 2019-05-15 | 2021-04-13 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
| MX2021015827A (es) * | 2019-06-28 | 2022-04-11 | Shanghai Shengdi Pharmaceutical Co Ltd | Antagonista de neurokinin -1. |
| IL296635A (en) | 2020-04-03 | 2022-11-01 | Nerre Therapeutics Ltd | An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS) |
| KR20230018485A (ko) | 2020-06-02 | 2023-02-07 | 네르 쎄라퓨틱스 리미티드 | 폐에 대한 기계적 손상에 의해 촉진된 폐 섬유증 상태의 치료에 사용하기 위한 뉴로키닌 (nk)-1 수용체 길항제 |
| EP4268818A4 (en) * | 2020-12-25 | 2024-06-19 | Shanghai Shengdi Pharmaceutical Co Ltd | USE OF AN NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH A 5-HT3 RECEPTOR ANTAGONIST |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2791346B3 (fr) * | 1999-03-25 | 2001-04-27 | Sanofi Sa | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN |
| PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
-
2004
- 2004-12-20 WO PCT/US2004/042893 patent/WO2005063243A1/en active Application Filing
- 2004-12-20 JP JP2006545570A patent/JP2007515425A/ja not_active Withdrawn
- 2004-12-20 EP EP04815019A patent/EP1706116A1/en not_active Withdrawn
- 2004-12-20 MX MXPA06007210A patent/MXPA06007210A/es not_active Application Discontinuation
- 2004-12-20 BR BRPI0417950-1A patent/BRPI0417950A/pt not_active Application Discontinuation
- 2004-12-20 PL PL380482A patent/PL380482A1/pl not_active Application Discontinuation
- 2004-12-20 CA CA002550432A patent/CA2550432A1/en not_active Abandoned
- 2004-12-20 CN CNA200480038273XA patent/CN1897942A/zh active Pending
- 2004-12-20 TW TW093139690A patent/TW200531686A/zh unknown
- 2004-12-20 AU AU2004308935A patent/AU2004308935A1/en not_active Abandoned
- 2004-12-20 AR ARP040104804A patent/AR046769A1/es not_active Application Discontinuation
- 2004-12-20 US US11/017,156 patent/US20050153999A1/en not_active Abandoned
- 2004-12-20 KR KR1020067012300A patent/KR20060113737A/ko not_active Application Discontinuation
-
2005
- 2005-01-03 PE PE2005000022A patent/PE20051049A1/es not_active Application Discontinuation
-
2006
- 2006-06-20 ZA ZA200605080A patent/ZA200605080B/xx unknown
- 2006-07-21 NO NO20063393A patent/NO20063393L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200605080B (en) | 2008-06-25 |
| TW200531686A (en) | 2005-10-01 |
| AR046769A1 (es) | 2005-12-21 |
| WO2005063243A1 (en) | 2005-07-14 |
| US20050153999A1 (en) | 2005-07-14 |
| MXPA06007210A (es) | 2006-08-18 |
| EP1706116A1 (en) | 2006-10-04 |
| AU2004308935A1 (en) | 2005-07-14 |
| PL380482A1 (pl) | 2007-02-05 |
| CN1897942A (zh) | 2007-01-17 |
| NO20063393L (no) | 2006-07-21 |
| JP2007515425A (ja) | 2007-06-14 |
| BRPI0417950A (pt) | 2007-04-17 |
| KR20060113737A (ko) | 2006-11-02 |
| CA2550432A1 (en) | 2005-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051049A1 (es) | Composiciones farmaceuticas que comprenden un antagonista de neuroquinina nk1 | |
| AR053412A1 (es) | Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos | |
| NO20043367L (no) | Oralt farmasoytisk preparat | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| CO5630034A2 (es) | Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
| AR033999A1 (es) | Derivados de sulfonamida farmaceuticamente activos que incluyen fracciones lipofilicas e ionizables como inhibidores de las proteinas junquinasas | |
| UY31870A (es) | Receptor metabotrópico de glutamato potenciadores 286 | |
| AR032335A1 (es) | Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos | |
| BRPI0014869B8 (pt) | prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização | |
| SE0302760D0 (sv) | New compounds | |
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| JP4979258B2 (ja) | アシタザノラスト含有水性組成物 | |
| NO20083027L (no) | Kontrollert frigivelses-fastformpreparat | |
| JP2020138979A (ja) | 眼科用組成物 | |
| CL2008003811A1 (es) | Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor. | |
| AR029373A1 (es) | Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas | |
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| AR046756A1 (es) | Derivados de hidronopol como agonistas de receptores orl-1 humanos. | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| JP5052028B2 (ja) | アシタザノラスト含有組成物 | |
| CR8384A (es) | Metodos y composiciones para la inhibicion de selectina | |
| EA200300406A1 (ru) | Фармацевтическая композиция дронедарона для парентерального введения | |
| CY1114850T1 (el) | Αντικαρκινικη ενωση και η φαρμακευτικη συνθεση που την περιεχει | |
| AR016382A1 (es) | Uso de un derivado del acido bencil-indazol metoxialcanoico. | |
| UY27034A1 (es) | Derivados de pirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |